Compare · ARGX vs BTTC
ARGX vs BTTC
Side-by-side comparison of argenx SE (ARGX) and Black Titan Corporation (BTTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BTTC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $56.09B, about 53611.0x BTTC ($1.0M).
- Over the past year, ARGX is up 66.9% and BTTC is down 82.7% - ARGX leads by 149.6 points.
- ARGX has been more active in the news (3 items in the past 4 weeks vs 2 for BTTC).
- ARGX has more recent analyst coverage (25 ratings vs 0 for BTTC).
- Company
- argenx SE
- Black Titan Corporation
- Price
- $904.59+3.04%
- $0.76-4.59%
- Market cap
- $56.09B
- $1.0M
- 1M return
- +12.45%
- -33.04%
- 1Y return
- +66.87%
- -82.73%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 3
- 2
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Latest BTTC
- SEC Form 6-K filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation
- SEC Form EFFECT filed by Black Titan Corporation
- Amendment: SEC Form F-1/A filed by Black Titan Corporation
- Institutional Infrastructure Note: The Convergence of Pre-IPO Equity, Agentic Finance, and Neobank Charters
- Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
- SEC Form 6-K filed by Black Titan Corporation
- Institutional Digital Asset Infrastructure: The Maturation of Yield Routing and Restaking Rails
- SEC Form 6-K filed by Black Titan Corporation